{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:02:43Z","timestamp":1794430963473,"version":"4.9.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Deficiency of adenosine deaminase-2 (DADA2) is an autosomal recessive autoinflammatory disease with an extremely variable disease presentation. This paper provides a comprehensive overview of the Dutch DADA2 cohort. We performed a retrospective cohort study in 29 ADA2-deficient patients from 23 families with a median age at inclusion of 26\u00a0years. All patients had biallelic pathogenic variants in the <jats:italic>ADA2<\/jats:italic> gene. The most common clinical findings included cutaneous involvement (79.3%), (hepato)splenomegaly (70.8%) and recurrent infections (58.6%). Stroke was observed in 41.4% of the patients. The main laboratory abnormalities were hypogammaglobulinemia and various cytopenias. Patients presented most often with a mixed phenotype involving vasculopathy, immunodeficiency and hematologic manifestations (62.1%). In this cohort, malignancies were reported in eight patients (27.6%), of whom five presented with a hematologic malignancy and two with a basal cell carcinoma. Four patients developed hemophagocytic lymphohistiocytosis (HLH) or an HLH-like episode, of whom three passed away during or shortly after the occurrence of HLH. TNF-inhibitors (TNFi) were effective in treating vasculopathy-associated symptoms and preventing stroke, but were hardly effective in the treatment of hematologic manifestations. Three patients underwent hematopoietic cell transplantation and two of them are doing well with complete resolution of DADA2-related symptoms. The overall mortality in this cohort was 17.2%. In conclusion, this cohort describes the clinical, genetic and laboratory findings of 29 Dutch DADA2 patients. We describe the occurrence of HLH as a life-threatening disease complication and report a relatively high incidence of malignancies and mortality.<\/jats:p>","DOI":"10.1007\/s10875-023-01521-8","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T17:02:01Z","timestamp":1685984521000},"page":"1581-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort"],"prefix":"10.1007","volume":"43","author":[{"given":"Marie Val\u00e9rie E.","family":"Andriessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Elizabeth","family":"Legger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert G. M.","family":"Bredius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marielle E.","family":"van Gijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Elisabeth","family":"Hak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra C. E. Hissink","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Kamphuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke C. C.","family":"Klouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taco W.","family":"Kuijpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen L.","family":"Leavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Nierkens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Rutgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars T.","family":"van der Veken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gijs T. J.","family":"van Well","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina M.","family":"Mulders-Manders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6764-0211","authenticated-orcid":false,"given":"Joris M.","family":"van Montfrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"issue":"10","key":"1521_CR1","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"1521_CR2","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1056\/NEJMoa1307362","volume":"370","author":"P Navon Elkan","year":"2014","unstructured":"Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padeh S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921\u201331.","journal-title":"N Engl J Med"},{"key":"1521_CR3","doi-asserted-by":"crossref","unstructured":"Meyts I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569\u201378.","DOI":"10.1007\/s10875-018-0525-8"},{"key":"1521_CR4","doi-asserted-by":"crossref","unstructured":"Lee PY. Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2. Front Pediatr. 2018;18;6:282.","DOI":"10.3389\/fped.2018.00282"},{"issue":"8","key":"1521_CR5","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.40147","volume":"69","author":"J Schepp","year":"2017","unstructured":"Schepp J, Proietti M, Frede N, Buchta M, H\u00fcbscher K, Rojas Restrepo J, et al. Screening of 181 patients with antibody deficiency for deficiency of adenosine deaminase 2 sheds new light on the disease in adulthood. Arthritis Rheumatol. 2017;69(8):1689\u2013700.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"1521_CR6","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.jaci.2019.12.908","volume":"145","author":"PY Lee","year":"2020","unstructured":"Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020;145(6):1664-1672.e10. https:\/\/doi.org\/10.1016\/j.jaci.2019.12.908.","journal-title":"J Allergy Clin Immunol."},{"issue":"9","key":"1521_CR7","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/art.39699","volume":"68","author":"S Nanthapisal","year":"2016","unstructured":"Nanthapisal S, Murphy C, Omoyinmi E, Hong Y, Standing A, Berg S, et al. Deficiency of adenosine deaminase type 2: a description of phenotype and genotype in fifteen cases. Arthritis Rheumatol. 2016;68(9):2314\u201322.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"1521_CR8","first-page":"902","volume":"55","author":"JM Van Montfrans","year":"2016","unstructured":"Van Montfrans JM, Hartman EAR, Braun KPJ, Hennekam EAM, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatol (United Kingdom). 2016;55(5):902\u201310.","journal-title":"Rheumatol (United Kingdom)"},{"issue":"5","key":"1521_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3899\/jrheum.180045","volume":"46","author":"A Insalaco","year":"2019","unstructured":"Insalaco A, Moneta GM, Pardeo M, Caiello I, Messia V, Bracaglia C, et al. Variable clinical phenotypes and relation of interferon signature with disease activity in ADA2 deficiency. J Rheumatol. 2019;46(5):523\u20136.","journal-title":"J Rheumatol"},{"issue":"3","key":"1521_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/JLB.3HI0220-119RR","volume":"110","author":"N Watanabe","year":"2021","unstructured":"Watanabe N, Gao S, Wu Z, Batchu S, Kajigaya S, Diamond C, et al. Analysis of deficiency of adenosine deaminase 2 pathogenesis based on single-cell RNA sequencing of monocytes. J Leukoc Biol. 2021;110(3):409\u201324.","journal-title":"J Leukoc Biol"},{"issue":"1","key":"1521_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-12-44","volume":"12","author":"A Belot","year":"2014","unstructured":"Belot A, Wassmer E, Twilt M, Lega JC, Zeef LAH, Oojageer A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood. Pediatr Rheumatol. 2014;12(1):1\u20137.","journal-title":"Pediatr Rheumatol"},{"issue":"4","key":"1521_CR12","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1182\/blood.2018892752","volume":"134","author":"C Carmona-Rivera","year":"2019","unstructured":"Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O\u2019Neil LJ, Liu Y, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood. 2019;134(4):395\u2013406.","journal-title":"Blood"},{"issue":"7","key":"1521_CR13","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.4049\/jimmunol.168.7.3536","volume":"168","author":"K-U Belge","year":"2002","unstructured":"Belge K-U, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, et al. The proinflammatory CD14 + CD16 + DR ++ monocytes are a major source of TNF. J Immunol. 2002;168(7):3536\u201342.","journal-title":"J Immunol"},{"issue":"January","key":"1521_CR14","first-page":"1","volume":"12","author":"KS Barron","year":"2022","unstructured":"Barron KS, Aksentijevich I, Deuitch NT, Stone DL, Hoffmann P, Videgar-Laird R, et al. The spectrum of the deficiency of adenosine deaminase 2: an observational analysis of a 60 patient cohort. Front Immunol. 2022;12(January):1\u201318.","journal-title":"Front Immunol"},{"issue":"10","key":"1521_CR15","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/annrheumdis-2016-210802","volume":"76","author":"R Caorsi","year":"2017","unstructured":"Caorsi R, Penco F, Grossi A, Insalaco A, Omenetti A, Alessio M, et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study. Ann Rheum Dis. 2017;76(10):1648\u201356.","journal-title":"Ann Rheum Dis"},{"issue":"16","key":"1521_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMc1801927","volume":"380","author":"AK Ombrello","year":"2019","unstructured":"Ombrello AK, Qin J, Hoffmann PM, Kumar P, Stone D, Jones A, et al. Treatment strategies for deficiency of adenosine deaminase 2. N Engl J Med. 2019;380(16):1582\u20134.","journal-title":"N Engl J Med"},{"issue":"9","key":"1521_CR17","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1093\/rheumatology\/keaa837","volume":"60","author":"S Cooray","year":"2021","unstructured":"Cooray S, Omyinmi E, Hong Y, Papadopoulou C, Harper L, Al-Abadi E, et al. Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). Rheumatology (Oxford). 2021;60(9):4373\u20138.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"1521_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jaci.2014.10.010","volume":"135","author":"L Van Eyck","year":"2015","unstructured":"Van Eyck L, Hershfield MS, Pombal D, Kelly SJ, Ganson NJ, Moens L, et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency. J Allergy Clin Immunol. 2015;135(1):283-287.e5.","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"1521_CR19","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s10875-021-01098-0","volume":"41","author":"H Hashem","year":"2021","unstructured":"Hashem H, Bucciol G, Ozen S, Unal S, Bozkaya IO, Akarsu N, et al. Hematopoietic cell transplantation cures adenosine deaminase 2 deficiency: report on 30 patients. J Clin Immunol. 2021;41(7):1633\u201347. https:\/\/doi.org\/10.1007\/s10875-021-01098-0.","journal-title":"J Clin Immunol."},{"issue":"7","key":"1521_CR20","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/annrheumdis-2011-200549","volume":"71","author":"N Toplak","year":"2012","unstructured":"Toplak N, Frenkel J, Ozen S, Lachmann HJ, Woo P, Kon\u00e9-Paut I, et al. An international registry on autoinflammatory diseases: the Eurofever experience. Ann Rheum Dis. 2012;71(7):1177\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1521_CR21","first-page":"142","volume":"37","author":"GTJ van Well","year":"2019","unstructured":"van Well GTJ, Kant B, van Nistelrooij A, SirmaEkmekci S, Henriet SV, Hoppenreijs E, et al. Phenotypic variability including Beh\u00e7et\u2019s disease-like manifestations in DADA2 patients due to a homozygous c.973\u20132A>G splice site mutation. Clin Exp Rheumatol. 2019;37(6):142\u20136.","journal-title":"Clin Exp Rheumatol."},{"issue":"1","key":"1521_CR22","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaci.2021.04.034","volume":"149","author":"H Jee","year":"2022","unstructured":"Jee H, Huang Z, Baxter S, Huang Y, Taylor ML, Henderson LA, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency driven by a function-based approach. J Allergy Clin Immunol. 2022;149(1):379\u201387. https:\/\/doi.org\/10.1016\/j.jaci.2021.04.034.","journal-title":"J Allergy Clin Immunol."},{"issue":"2","key":"1521_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1615\/CritRevEukarGeneExpr.v20.i2.10","volume":"20","author":"N Parameswaran","year":"2010","unstructured":"Parameswaran N, Patial S. Tumor necrosis factor-a signaling in macrophages. Crit Rev Eukaryot Gen Expr. 2010;20(2):87\u2013103.","journal-title":"Crit Rev Eukaryot Gen Expr"},{"issue":"4","key":"1521_CR24","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.jaci.2018.01.012","volume":"141","author":"L Trotta","year":"2018","unstructured":"Trotta L, Martelius T, Siitonen T, Hautala T, H\u00e4m\u00e4l\u00e4inen S, Juntti H, et al. ADA2 deficiency: clonal lymphoproliferation in a subset of patients. J Allergy Clin Immunol [Internet]. 2018;141(4):1534-1537.e8. https:\/\/doi.org\/10.1016\/j.jaci.2018.01.012.","journal-title":"J Allergy Clin Immunol [Internet]."},{"issue":"215","key":"1521_CR25","first-page":"22","volume":"2020","author":"E Staples","year":"2020","unstructured":"Staples E, Simeoni I, Stephens JC, Allen HL, Wright P, Davies EG, et al. ADA2 deficiency complicated by EBV-driven lymphoproliferative disease. Clin Immunol. 2020;2020(215):22\u20135.","journal-title":"Clin Immunol"},{"issue":"1","key":"1521_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2141.2007.06620.x","volume":"138","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Attygalle AD, Chuang SS, Diss T, Ye H, Liu H, et al. Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. Br J Haematol. 2007;138(1):44\u201353.","journal-title":"Br J Haematol"},{"issue":"9","key":"1521_CR27","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1182\/blood-2016-08-692590","volume":"129","author":"T Lamy","year":"2017","unstructured":"Lamy T, Moignet A, Loughran TP. LGL leukemia: from pathogenesis to treatment. Blood. 2017;129(9):1082\u201394. https:\/\/doi.org\/10.1182\/blood-2016-08-692590.","journal-title":"Blood."},{"issue":"8","key":"1521_CR28","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1007\/s10875-018-0565-0","volume":"38","author":"K Arts","year":"2018","unstructured":"Arts K, Bergerson JRE, Ombrello AK, Similuk M, Oler AJ, Agharahimi A, et al. Warts and DADA2: a mere coincidence? J Clin Immunol. 2018;38(8):836\u201343.","journal-title":"J Clin Immunol"},{"key":"1521_CR29","doi-asserted-by":"crossref","unstructured":"Batu ED, Karadag O, Taskiran EZ, Kalyoncu U, Aksentijevich I, Alikasifoglu M, et al. A case series of adenosine deaminase 2 deficient patients emphasizing treatment and genotype-phenotype correlations. Pediatr Rheumatol. 2015;13(1):P62. Available from:\u00a0http:\/\/www.ped-rheum.com\/content\/13\/S1\/P62. Accessed 1 Nov 2022","DOI":"10.1186\/1546-0096-13-S1-P62"},{"issue":"2","key":"1521_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1159\/000338179","volume":"128","author":"A Flammiger","year":"2012","unstructured":"Flammiger A, Fiedler W, Bacher U, Bokemeyer C, Schneider M, Binder M. Critical imbalance of TNF-\u03b1 and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment. Acta Haematol. 2012;128(2):69\u201372.","journal-title":"Acta Haematol"},{"issue":"9","key":"1521_CR31","first-page":"2120","volume":"28","author":"S Prahalad","year":"2001","unstructured":"Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA. Etanercept in the treatment of macrophage activation syndrome. J Rheumatol. 2001;28(9):2120\u20134.","journal-title":"J Rheumatol"},{"issue":"october","key":"1521_CR32","first-page":"55","volume":"10","author":"B Stanimirovi\u0107","year":"2015","unstructured":"Stanimirovi\u0107 B, Konjevi\u0107 S, \u0110ur\u0111evi\u0107-Banjac B, \u0110uki\u0107 D, Peji\u0107 D, Mr\u0111a J. Macrophage activation syndrome in a child with systemic onset of juvenile idiopathic arthritis. Signa Vitae. 2015;10(october):55\u20137.","journal-title":"Signa Vitae"},{"issue":"7","key":"1521_CR33","first-page":"443","volume":"12","author":"G Sterba","year":"2010","unstructured":"Sterba G, Sterba Y, Stempel C, Blank J, Azor E, Gomez L. Macrophage activation syndrome induced by etanercept in a patient with systemic sclerosis. Isr Med Assoc J. 2010;12(7):443\u20135.","journal-title":"Isr Med Assoc J"},{"key":"1521_CR34","doi-asserted-by":"crossref","unstructured":"Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4).","DOI":"10.1016\/j.berh.2020.101515"},{"key":"1521_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.00119","volume":"10","author":"CB Crayne","year":"2019","unstructured":"Crayne CB, Albeituni S, Nichols KE, Cron RQ. The immunology of macrophage activation syndrome. Front Immunol. 2019;10:1\u201311.","journal-title":"Front Immunol."},{"key":"1521_CR36","doi-asserted-by":"crossref","unstructured":"Lee PY, Schulert GS, Canna SW, Huang Y, Sundel J, Li Y, et al. Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Ann Rheum Dis. 2019;225\u201331.","DOI":"10.1136\/annrheumdis-2019-216030"},{"key":"1521_CR37","doi-asserted-by":"crossref","unstructured":"Sundin M, Marits P, Nierkens S, Kolios AGA, Nilsson J. Immune thrombocytopenia as key feature of a novel ADA2 deficiency variant: implication on differential diagnostics of ITP in children. J Pediatr Hematol Oncol. 2019;41(2):155\u20137.","DOI":"10.1097\/MPH.0000000000001132"},{"issue":"2","key":"1521_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s10875-018-0480-4","volume":"38","author":"TF Michniacki","year":"2018","unstructured":"Michniacki TF, Hannibal M, Ross CW, Frame DG, DuVall AS, Khoriaty R, et al. Hematologic manifestations of deficiency of adenosine deaminase 2 (DADA2) and response to tumor necrosis factor inhibition in DADA2-associated bone marrow failure. J Clin Immunol. 2018;38(2):166\u201373.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1521_CR39","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1080\/03009742.2020.1772868","volume":"50","author":"D Keino","year":"2021","unstructured":"Keino D, Kondoh K, Kim Y, Sudo A, Ohyama R, Morimoto M, et al. Successful treatment with cyclosporine and anti-tumour necrosis factor agent for deficiency of adenosine deaminase-2. Scand J Rheumatol. 2021;50(3):243\u20135. https:\/\/doi.org\/10.1080\/03009742.2020.1772868.","journal-title":"Scand J Rheumatol."},{"issue":"24","key":"1521_CR40","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1182\/blood-2017-07-798660","volume":"130","author":"H Hashem","year":"2017","unstructured":"Hashem H, Kumar AR, M\u00fcller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682\u20138.","journal-title":"Blood"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01521-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-023-01521-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-023-01521-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T08:08:07Z","timestamp":1694592487000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-023-01521-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s10875-023-01521-8","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"3 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is an observational study. The UMC Utrecht Research Ethics Committee has confirmed that no ethical approval is required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors affirm that human research participant provided informed consent for publication of the individual information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing \ninterests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}